

Contents

Contributors, ix

Historical introduction, xv

Christine A. Lee

PART I: Introduction

- 1 Overview of hemostasis, 3
Kathleen Brummel Ziedins and Kenneth G. Mann
- 2 Cellular processing of factor VIII and factor IX, 9
Michael U. Callaghan and Randal J. Kaufman

PART II: Hemophilia A

- 3 Molecular basis of hemophilia A, 23
Geoffrey Kembball-Cook and Keith Gomez
- 4 Prophylaxis, 33
Kathelijne Fischer and H. Marijke van den Berg

PART III: Inhibitors to factor VIII

- 5 Inhibitors to factor VIII: immunology, 43
Jean-Marie R. Saint-Remy and Marc G. Jacquemin
- 6 Genetic and environmental risk factors for factor VIII inhibitor development, 48
Jan Astermark
- 7 Epidemiology of inhibitors in hemophilia, 53
Alfonso Iorio
- 8 Inhibitors to factor VIII: mild and moderate hemophilia, 59
Kathelijne Peerlinck and Marc Jacquemin
- 9 Inhibitors to factor VIII/IX: immune tolerance, 64
Donna M. DiMichele
- 10 Prophylaxis in inhibitor patients, 72
Alessandro Gringeri
- 11 Inhibitors to factor VIII: treatment of acute bleeds, 78
Claude Negrier

PART IV: Acquired hemophilia

- 12 Acquired inhibitors to factor VIII, 87
Craig M. Kessler

PART V: Hemophilia B

- 13 Hemophilia B: molecular basis, 97
Keith Gomez and Pratima Chowdary
- 14 Factor IX inhibitors in hemophilia B, 103
Meera B. Chitlur and Jeanne M. Lusher
- 15 Treatment of inhibitors in hemophilia B, 107
Anand Tandra and Amy D. Shapiro

PART VI: Pharmacokinetics of factors VIII and IX

- 16 Pharmacokinetics, 117
Sven Björkman
- 17 Individualized dosing, 123
Peter W. Collins

PART VII: Hemophilia: birth to old age

- 18 Neonate with hemophilia, 131
Angela E. Thomas and Elizabeth A. Chalmers
- 19 Work-up of a bleeding child, 138
Manuel D. Carcao and Victor S. Blanchette
- 20 Care of the child with hemophilia, 145
Rolf C.R. Ljung
- 21 Hemophilia in adolescence, 150
Pia Petrini
- 22 Old age medicine and hemophilia, 154
Evelien P. Mauser-Bunschoten and Roger E.G. Schutgens

PART VIII: Products used to treat hemophilia

- 23 Products used to treat hemophilia: recombinant products, 165
Midori Shima and Akira Yoshioka
- 24 Products used to treat hemophilia: plasma-derived coagulation factor concentrates, 174
Paul L.F. Giangrande
- 25 Products used to treat hemophilia: dosing, 180
Miguel A. Escobar
- 26 Products used to treat hemophilia: regulation, 185
Albert Farrugia

- 27** New drugs in the pipeline: from concept to clinic, 192
Leonard A. Valentino

PART IX: Surgical management

- 28** General surgical management of patients with hemophilia, 199
Cindy Leissing and Rebecca Kruse-Jarres
- 29** Continuous infusion of coagulation products in hemophilia, 204
Angelika Batorova and Uri Martinowitz
- 30** Surgery in inhibitor patients, 213
Pål André Holme

PART X: Musculoskeletal

- 31** Joint replacement in patients with hemophilia, 221
Nicholas Goddard
- 32** Medical synovectomy (synoviorthesis) in hemophilia: radiosynovectomy and chemical synovectomy, 228
E. Carlos Rodriguez-Merchan
- 33** Pseudotumors in patients with hemophilia, 233
Michael Heim and Uri Martinowitz
- 34** Imaging modalities for assessment of hemophilic arthropathy, 237
Andrea S. Doria and Björn Lundin
- 35** Physiotherapy in the management of hemophilia, 247
Sébastien Lobet and David Stephensen
- 36** Outcome assessment in hemophilia, 253
Pradeep M. Poonmoose and Alok Srivastava

PART XI: Transfusion-transmitted disease

- 37** Viral hepatitis and hemophilia, 265
Michael Makris and Geoffrey Dusheiko
- 38** Transfusion-transmitted disease: emerging infections, 272
Thomas R. Kreil
- 39** vCJD and hemophilia, 277
Carolyn M. Millar

PART XII: Gene therapy

- 40** Hemophilia gene therapy: an overview, 285
David Lillicrap
- 41** Gene therapy trials in hemophilia A and B, 291
Katherine A. High
- 42** Gene therapy: molecular engineering of factor VIII and factor IX, 298
Sundar R. Selvaraj and Steven W. Pipe

PART XIII: Laboratory

- 43** Laboratory and quality control of assays, 311
Steve Kitchen
- 44** Standardization of assays in hemophilia, 318
Sanj Raut and Trevor W. Barrowcliffe
- 45** Global laboratory assays in hemophilia, 328
Benny Sørensen and Guy Young

PART XIV: Women and bleeding disorders

- 46** Obstetrics and gynecology: hemophilia, 337
Rezan A. Kadir and Christine A. Lee
- 47** Women and von Willebrand disease, 345
Peter A. Kouides

PART XV: von Willebrand disease

- 48** von Willebrand disease: molecular aspects, 355
Daniel Hampshire and Anne Goodeve
- 49** von Willebrand disease: epidemiology, 362
Francesco Rodeghiero and Giancarlo Castaman
- 50** von Willebrand disease: biological diagnosis, 370
Veronica H. Flood and Robert R. Montgomery
- 51** Classification and clinical aspects of von Willebrand disease, 377
Augusto B. Federici
- 52** Treatment of von Willebrand disease: desmopressin, 386
Pier M. Mannucci
- 53** Treatment of von Willebrand disease: therapeutic concentrates, 390
Erik E. Berntorp

PART XVI: Rare bleeding disorders

- 54** Factor II, 399
Jan Astermark
- 55** Factor V and combined factor V and VIII deficiencies, 403
Flora Peyvandi and Marzia Menegatti
- 56** Congenital factor VII deficiency, 413
Angelika Batorova
- 57** Factor X and factor X deficiency, 421
David J. Perry
- 58** Factor XI deficiency, 428
Paula H.B. Bolton-Maggs and Uri Seligsohn
- 59** Factor XIII deficiency, 436
Diane Nugent and Loan Hsieh
- 60** Fibrinogen deficiency, 445
Michael Laffan

61 Miscellaneous rare bleeding disorders, 452*Frederico Xavier and Amy D. Shapiro***PART XVII: Emergency medicine****62** Emergency management of hemophilia, 463*W. Keith Hoots***PART XVIII: Evaluation of hemophilia****63** Clinical trials and other methodologies, 473*Sharyne M. Donfield and Alice E. Lail***64** Quality of life in hemophilia, 478*Sylvia von Mackensen and Alessandro Gringeri***65** The economics of hemophilia treatment, 489*Katarina Steen Carlsson and Erik E. Berntorp***PART XIX: Comprehensive care and delivery of care****66** Hemophilia databases, 497*Charles R.M. Hay***Angelika Satorova, MD, PhD**

Associate Professor
Director of the National Hemophilia Center
Departments of Hematology & Transfusion Medicine
Medical School of Comenius University, University Hospital
Bratislava, Slovakia

H. Marijke van den Berg, MD, PhD

Pediatric Hematologist
John Center for Health Sciences and Primary Care
University Medical Center
Gronovo, the Netherlands

Erik E. Berntorp, MD, PhD

Professor of Coagulation Medicine
Lund University
Malmö Centre for Thrombosis and Haemostasis
Skåne University Hospital
Malmö, Sweden

Sven Björkman, PhD (deceased)

Professor of Pharmacokinetics
Department of Pharmaceutical Biosciences
Uppsala University
Uppsala, Sweden

Victor S. Blanchette, FRCP

Professor of Paediatrics
Medical Director, Paediatric Thrombosis and Haemostasis Program
Division of Hematology/Oncology
The Hospital for Sick Children
University of Toronto
Toronto, ON, Canada

67 Comprehensive care and delivery of care: the developed world, 502*Christopher A. Ludlam and Cedric R.J.R. Hermans***68** Comprehensive care and delivery of care in hemophilia: the developing world, 508*Alok Srivastava and Auro Viswabandya***69** Comprehensive care and delivery of care: the global perspective, 515*Mark W. Skinner and Alison M. Street*

Paediatric Haematologist, FRCP, FRCPath
Consultant Haematologist, Manchester Blood Centre and Honorary Senior Lecturer

Index, 523

Color plate section can be found facing page 202

Kathleen Brummel Ziedins, PhD

Associate Professor
Department of Biochemistry
University of Vermont
College of Medicine
Colchester, VT, USA

Michael U. Callaghan, MD

Assistant Professor of Pediatrics
Children's Hospital of Michigan
Wayne State University
Department of Pediatrics
Detroit, MI, USA

Manuel D. Carcao, MD, FRCP(C), MSc

Associate Professor of Paediatrics
Division of Haematology/Oncology and Child Health/Executive Sciences
The Hospital for Sick Children
University of Toronto
Toronto, ON, Canada

Giancarlo Castaman, MD

Consultant Haematologist
Department of Cell Therapy and Hematology
Hemophilia and Thrombosis Center
San Bortolo Hospital
Vicenza, Italy

Elizabeth A. Chalmers, MR, ChB, MD, MRCP(UK)

FRCPath
Consultant Paediatric Haematologist
Royal Hospital for Sick Children
Yorkhill
Glasgow, Scotland

Meera B. Chitlur, MD

Associate Professor of Pediatrics
Wayne State University School of Medicine
Bernhart Fisher Hemostasis Research
Endowed Chair
Director, Hemophilia Treatment Center and Hemostasis Program
Division of Hematology/Oncology
Children's Hospital of Michigan
Detroit, MI, USA